Wegovy Pill Linked to 4.1% Weight Loss After Switching from Injections

Recent findings from the OCTANE study suggest that individuals with overweight or obesity may experience additional weight loss after switching from injectable GLP-1 medications to the Wegovy pill (semaglutide). Conducted in a real-world setting, this research indicates that participants lost an average of 4.1% of their body weight over a three-month period following the transition.

Presenting the results at the 2026 Meeting of the European Association for the Study of Diabetes in Milan, Italy, the study highlights the potential benefits of switching to the oral formulation of semaglutide for weight management. Approximately 40% of the participants reported losing at least 5% of their body weight during the study, showcasing significant progress in their weight loss journeys.

The study analyzed data from 194 adults who were previously using injectable semaglutide or tirzepatide for weight management. All participants had at least one obesity-related health condition, such as hypertension, cardiovascular issues, obstructive sleep apnea, or dyslipidemia. Participants averaged a starting weight of 221.6 pounds with a body mass index (BMI) of 34.5 kg/m².

Participants made the switch from injections to the Wegovy pill between January 5 and February 7, 2026. They were instructed to take the oral medication consistently for three months, reporting their weight at the beginning and the end of the study. The results revealed an average weight loss of 8.8 pounds among the group, with a notable decrease in the percentage of participants classified as obese, dropping from 87.1% to 65.5% over the study period.

In addition to weight loss, the majority of participants (82.4%) reported experiencing at least one improvement in their treatment, with 69% noting that their clothes fit better and 51% indicating they were making healthier dietary choices.

Dr. Betul Hatipoglu, Medical Director of the Diabetes & Metabolic Center at University Hospitals in Cleveland, commented on the findings, stating that the results are promising. However, she emphasized that while the data is encouraging, it should be viewed as preliminary evidence rather than conclusive proof of improved outcomes from switching to the oral treatment.

When considering whether to use the Wegovy pill or the injectable form, Dr. Mir Ali, Medical Director of the MemorialCare Surgical Weight Loss Center, noted that the oral version may be easier for some patients due to its convenience and lack of refrigeration requirements. However, he cautioned that the oral medication is absorbed differently, which may affect its efficacy compared to the injectable format.

Both forms of semaglutide can lead to gastrointestinal side effects, such as nausea and diarrhea, and patients should discuss the best option based on their individual circumstances, including treatment effectiveness, side effects, and personal preferences. Ultimately, effective weight management requires a holistic approach, incorporating a healthy diet and lifestyle changes alongside medication.